Melek Simsek, Femke Schepers, Sigal Kaplan, Dirk van Asseldonk, Petra van Boeckel, Paul Boekema, Gerard Dijkstra, Herma Fidder, Ingrid Gisbertz, Frank Hoentjen, Bindia Jharap, Frank Kubben, Marleen de Leest, Maarten Meijssen, Ana Petrak, Else van de Poel, Maurice Russel, Adriaan A van Bodegraven, Chris J J Mulder, Nanne de Boer
BACKGROUND AND AIMS: Thioguanine is a well-tolerated and effective therapy for inflammatory bowel disease [IBD] patients. Prospective effectiveness data are needed to substantiate the role of thioguanine as a maintenance therapy for IBD. METHODS: IBD patients who previously failed azathioprine or mercaptopurine and initiated thioguanine were prospectively followed for 12 months starting when corticosteroid-free clinical remission was achieved (Harvey-Bradshaw Index [HBI] ≤ 4 or Simple Clinical Colitis Activity Index [SCCAI] ≤ 2)...
June 16, 2023: Journal of Crohn's & Colitis